Who are Alzamend Neuro, Inc.'s main suppliers?

Alzamend Neuro, Inc. (ALZN) key suppliers include: ASCENDIANT-CAPITAL-MARKETS-LLC, LICENSOR, THIRD-PARTY-CONTRACTORS, AULT, SUBLICENSING-TERMS-FOR-ALZN002 and 2 more. View the full supplier network at chainsifter.com/chain/ALZN.

Who are Alzamend Neuro, Inc.'s major customers?

Alzamend Neuro, Inc. (ALZN) key customers include: BIOPHARMACEUTICAL-COMPANIES, ORANY, ORANY, AULT-ALLIANCE-INC, CAPITAL-RESOURCES and 1 more. View the full customer network at chainsifter.com/chain/ALZN.

What sector is Alzamend Neuro, Inc. in?

Alzamend Neuro, Inc. (ALZN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Alzamend Neuro, Inc. Supplier List (ALZN): 7 Verified Suppliers

7Suppliers

6Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Alzamend Neuro, Inc. (ALZN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

4Distinct source URLs

9High confidence

0.797Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Alzamend Neuro, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ASCENDIANT-CAPITAL-MARKETS-LLC	ASCENDIANT-CAPITAL-MARKETS-LLC	92%	On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ A…
LICENSOR	LICENSOR	92%	The November AL001 License Agreements require the Company to pay royalty payments of 3 % on net sales of products developed from the licensed technology for AL001 in those fields.
THIRD-PARTY-CONTRACTORS	THIRD-PARTY-CONTRACTORS	92%	We have outsourced and expect to continue to outsource the manufacturing of our products to third party contractors with special capabilities to manufacture chemical drugs and biologic drug candidate…
AULT	AULT	85%	We utilize resources from AULT to act as our information technology department (the "IT Department"), which functions as our Information Security Advisory Team
SUBLICENSING-TERMS-FOR-ALZN002	SUBLICENSING-TERMS-FOR-ALZN002	80%	On May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from ALZN graph: These policies also outline processes to assess, identify, manage, and report cybersecurity risks and incidents. The…
ORANY	ORANY	72%	These policies also outline processes to assess, identify, manage, and report cybersecurity risks and incidents. The Info-Sec Policy applies to all persons working for the Company and any third parti…

Alzamend Neuro, Inc. Customers

Ticker	Name	Confidence	Evidence
BIOPHARMACEUTICAL-COMPANIES	BIOPHARMACEUTICAL-COMPANIES	90%	we intend to develop AL001 and ALZN002 through successive de-risking milestones towards regulatory approval and seek marketing approval of AL001 and ALZN002 or enter into partnering transactions with…
ORANY	ORANY	72%	tively manage the growth of our operations, or our company will suffer. Our initiation of operations has resulted in significantly higher operating expenses. Expansion of our operations, to include t…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from ALZN graph: tively manage the growth of our operations, or our company will suffer. Our initiation of operations has resulted in…
AULT-ALLIANCE-INC	AULT-ALLIANCE-INC	62%	. The weighted-average period over which such stock-based compensation expense will be recognized is approximately 1.3 years. 8. WARRANTS Warrant Issuances During 2024 During the year ended April 30,…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	rative expenses $ 2,700,185 $ 2,393,117 $ 307,068 13 % 26 Salaries and Benefits During the nine months ended January 31, 2026 and 2025, we incurred salaries and benefits of $761,000 and $780,000, res…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	tively manage the growth of our operations, or our company will suffer. Our initiation of operations has resulted in significantly higher operating expenses. Expansion of our operations, to include t…

Alzamend Neuro, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ALZN-DEBT-7710	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2022-01-31.
ALZN-DEBT-7709	Warrants outstanding: 24.35	90%	xbrl warrant detail from xbrl 2025-01-31.

Alzamend Neuro, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Alzamend Neuro, Inc..

Alzamend Neuro, Inc. Ownership

Holder	Name	Confidence	Evidence
ALZN-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC	GEODE CAPITAL MANAGEMENT, LLC	90%	13F overlay lists GEODE CAPITAL MANAGEMENT, LLC as top holder; 12 tracked holders.

Alzamend Neuro, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ORANY	ORANGE	100.00	1	['customer', 'supplier']
AMZE	Amaze Holdings, Inc.	50.00	2
DWTX	Dogwood Therapeutics, Inc.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
CHUC	Charlie's Holdings, Inc.	50.00	2
CLNE	Clean Energy Fuels Corp.	50.00	2
FENC	Fennec Pharmaceuticals Inc.	50.00	2
EQR	Equity Residential	50.00	2
CNOB	ConnectOne Bancorp, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
ESS	Essex Property Trust, Inc.	50.00	2
ED	Consolidated Edison, Inc.	50.00	2
CORT	Corcept Therapeutics Incorporated	50.00	2
BSBK	Bogota Financial Corp.	50.00	2
BLTE	Belite Bio, Inc	50.00	2

Alzamend Neuro, Inc. Supply Chain